Cirdan signs US distribution deal for cancer x-ray system
MEDICAL informatics and imaging technology company firm Cirdan in Lisburn has signed an exclusive agreement with a global global healthcare firm to distribute its breast cancer x-ray system in North America and Canada.
The deal has been secured with Beckton Dickinson & Company (BD) to distribute its CoreLite specimen radiography system, which helps to speed up breast cancer diagnosis and is currently being distributed by BD in Europe.
Cirdan, established a decade ago and operating from offices at the former Coca-Cola factory in Lambeg, produces a suite of informatics and imaging solutions alongside CoreLite.
These include the world-class ‘Ultra’ Laboratory Information System (LIS) which is designed to support clinical laboratory operations.
The new deal will see BD’s sales team promote CoreLite across the US and Canada, further strengthening the existing relationship between the two companies.
Cirdan's chief technology officer Stephen Dunniece said: “We are delighted to partner with BD. We have an existing presence in North America with our LIS business, but this is an exciting new development for our imaging division.”
He added: “As a team we are extremely proud of creating a product like CoreLite, which offers benefits like improved patient experience and reduced clinical procedure time.
“We’re excited that with the help of BD we will be able to expand the reach of this product and undoubtedly make a positive impact on people’s lives.”
Jennifer Lutjen, director of global marketing at BD said: “We were looking for a product that would complement our market leading breast biopsy systems and enhance our offering to our customers.
“CoreLite was the perfect fit for us. We have enjoyed a successful partnership with Cirdan in Europe, and we are looking forward to building on this here in the US.”
In February Cirdan confirmed its move to new headquarters, which will allow it to accommodate up to 150 staff, and its objective over the next 18 months is to grow its footprint in the US, Oceania and EMEA markets.